An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders
Sponsor: Massachusetts General Hospital
Listed as NCT01931033, this NA trial focuses on ASD and Autism Spectrum Disorders and remains completed. Sponsored by Massachusetts General Hospital, it has been updated 15 times since 2013, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Aug 2024 — Sep 2024 [monthly]
Completed NA
-
Jul 2024 — Aug 2024 [monthly]
Completed NA
-
Nov 2023 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting NA
▶ Show 10 earlier versions
-
Sep 2022 — Oct 2023 [monthly]
Active Not Recruiting NA
-
Sep 2021 — Sep 2022 [monthly]
Active Not Recruiting NA
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting NA
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Dec 2019 — Sep 2020 [monthly]
Active Not Recruiting NA
-
Oct 2019 — Dec 2019 [monthly]
Active Not Recruiting NA
-
Jun 2018 — Oct 2019 [monthly]
Active Not Recruiting NA
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Dec 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Massachusetts General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .